drugset / Trial / NCT04857437
Study in Healthy Adults Evaluating PF-07202954
RandomizedSequentialOpen-labelBasic science
Summary
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
Timeline
- Start
- 2021-05-13
- Primary completion
- 2021-09-17
- Completion
- 2021-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-07202954 | Unknown | 10 mg | Oral |
| Subject | PF-07202954 | Unknown | 30 mg | Oral |
| Subject | PF-07202954 | Unknown | 100 mg | Oral |
| Subject | PF-07202954 | Unknown | 300 mg | Oral |
| Subject | PF-07202954 | Unknown | 600 mg | Oral |
| Subject | PF-07202954 | Unknown | 900 mg | Oral |
| Subject | PF-07202954 | Unknown | 1200 mg | Oral |